In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth a...
SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...
ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around t...
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently dev...
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported b...
-Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGE...
The issuance of the amended Schedule M follows persistent advocacy from industry associations such as the Organization of Pharmaceutical Producers of India...
Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights for Greater Chinaand Singapore Transaction reflects the&...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...
The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1000 m...
© 2025 Biopharma Boardroom. All Rights Reserved.
